Brief: AC Immune Initiates Phase 1 Clinical Trial Of NLRP3 Inhibitor
24/02/2026 12:16
Feb 24 (Reuters) - AC Immune SA ACIU.O: AC IMMUNE INITIATES PHASE 1 CLINICAL TRIAL OF NLRP3 INHIBITOR AC IMMUNE SA - PHASE 1 RESULTS EXPECTED IN H2 2026 Source text: ID:nGNXvWxwr Further company coverage: ACIU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune AG
See all newsAC Immune rises after Parkinson's drug shows promise in mid-stage trial
Brief: Ac Immune Reports Positive Safety & Immunogenicity At Week-100 In Part 1 Of Vacsyn Phase 2 Trial Of Aci-7104
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health